Carillon Tower Advisers’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Carillon Tower Advisers’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-485,595	Closed	-$31.6M	–	501
2020 Q3	$31.6M	Buy	485,595 +20,878	+4%	+$1.37M	0.42%	63
2020 Q2	$34M	Sell	464,717 -57,100	-11%	-$3.04M	0.26%	122
2020 Q1	$15.5M	Hold	521,817	–	–	0.15%	208
2019 Q4	$28.4M	Sell	521,817 -168,600	-24%	-$8.35M	0.19%	189
2019 Q3	$28.8M	Hold	690,417	–	–	0.2%	171
2019 Q2	$30.2M	Hold	690,417	–	–	0.21%	169
2019 Q1	$35.5M	Hold	690,417	–	–	0.25%	150
2018 Q4	$25.5M	Hold	690,417	–	–	0.22%	180
2018 Q3	$25.9M	Hold	690,417	–	–	0.19%	195
2018 Q2	$27.3M	Hold	690,417	–	–	0.21%	163
2018 Q1	$16.9M	Hold	690,417	–	–	0.13%	224
2017 Q4	$18.6K	Buy	+690,417	New	+$19M	0.2%	182

Other funds holding BHVN

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

RP Management New York $139M AUM 37.98% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Carillon Tower Advisers's BHVN Position: Q4 2020 in Review

Carillon Tower Advisers sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2020, closing a stake of 485,595 shares — an estimated $31.6M sold.

Carillon Tower Advisers first reported a position in BHVN in Q4 2017 and held it in 12 quarters. The position peaked at $35.5M in Q1 2019. 238 funds tracked by Wall St. Rank hold BHVN as of Q4 2020.

Carillon Tower Advisers reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2020 after selling out during the quarter.
Carillon Tower Advisers sold 485,595 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2020, an estimated $31.6M.
Carillon Tower Advisers first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q4 2017 and held it in 12 quarters.
Carillon Tower Advisers's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $35.5M in Q1 2019.
238 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2020.

Based on Carillon Tower Advisers's 13F filing for Q4 2020, filed 12 Feb 2021.